3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Myeloid, Acute
141
Myelodysplastic Syndromes
66
Leukemia, Myelomonocytic, Chronic
33
Neoplasms
17
Leukemia
16
Recurrence
14
Hematologic Neoplasms
14
Multiple Myeloma
11
Lymphoma, Non-Hodgkin
9
Lymphoma
7
Carcinoma, Non-Small-Cell Lung
6
Primary Myelofibrosis
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Myeloproliferative Disorders
5
Lymphoma, Large B-Cell, Diffuse
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Neoplasm Metastasis
4
Leukemia, Myeloid
4
Hodgkin Disease
4
Hematologic Diseases
4
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Glioblastoma
3
Breast Neoplasms
3
Anemia, Refractory, with Excess of Blasts
3
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Renal Insufficiency
2
Interventions
sargramostim
2
Monatide (IMS 3015)
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Azacitidine
2
venetoclax
1
ruxolitinib
1
rucaparib
1
olaparib
1
cc-486
1
Pemetrexed
1
Observation
1
Nivolumab
1
Decitabine
1
Cytarabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pathologic Complete Response
×
Azacitidine
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA